Treace Medical Concepts, Inc. Operating Expenses
Treace Medical Concepts, Inc. (TMCI) reported Operating Expenses of $50.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-07
- Treace Medical Concepts, Inc. operating expenses for the quarter ending 2026-06-30 was $50.56M, a 7.60% decline year-over-year.
- Treace Medical Concepts, Inc. operating expenses for the quarter ending 2026-03-31 was $54.57M, a 5.05% decline year-over-year.
- Treace Medical Concepts, Inc. operating expenses for the quarter ending 2025-12-31 was $56.32M, a 1.15% increase year-over-year.
- Treace Medical Concepts, Inc. operating expenses for the quarter ending 2025-09-30 was $55.38M, a 8.03% increase year-over-year.
- Treace Medical Concepts, Inc. operating expenses for fiscal 2025 was $223.91M, a 0.02% decline from fiscal 2024.
- Treace Medical Concepts, Inc. operating expenses for fiscal 2024 was $223.95M, a 10.12% increase from fiscal 2023.
- Treace Medical Concepts, Inc. operating expenses for fiscal 2023 was $203.37M, a 34.55% increase from fiscal 2022.
- Treace Medical Concepts, Inc. operating expenses for fiscal 2022 was $151.15M, a 60.73% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $50.56M 10-Q · filed 2026-08-07 | $105.14M 10-Q · filed 2026-08-07 | $161.46M derived: sum of 3 quarters · filed 2026-08-07 | $216.84M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $54.57M 10-Q · filed 2026-05-08 | $110.90M derived: sum of 2 quarters · filed 2026-05-08 | $166.28M derived: sum of 3 quarters · filed 2026-05-08 | $221.00M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $56.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $111.70M derived: sum of 2 quarters · filed 2026-02-27 | $166.43M derived: sum of 3 quarters · filed 2026-08-07 | $223.91M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $55.38M 10-Q · filed 2025-11-06 | $110.11M derived: sum of 2 quarters · filed 2026-08-07 | $167.58M 10-Q · filed 2025-11-06 | $223.26M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $54.73M 10-Q · filed 2026-08-07 | $112.20M 10-Q · filed 2026-08-07 | $167.88M derived: sum of 3 quarters · filed 2026-08-07 | $219.15M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $57.48M 10-Q · filed 2026-05-08 | $113.16M derived: sum of 2 quarters · filed 2026-05-08 | $164.42M derived: sum of 3 quarters · filed 2026-05-08 | $221.48M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $55.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $106.95M derived: sum of 2 quarters · filed 2026-02-27 | $164.00M derived: sum of 3 quarters · filed 2026-02-27 | $223.95M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $51.27M 10-Q · filed 2025-11-06 | $108.32M derived: sum of 2 quarters · filed 2025-11-06 | $168.27M 10-Q · filed 2025-11-06 | $225.80M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-06-30 | $57.06M 10-Q · filed 2025-08-07 | $117.00M 10-Q · filed 2025-08-07 | $174.53M derived: sum of 3 quarters · filed 2026-02-27 | $225.11M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | $59.95M 10-Q · filed 2025-05-08 | $117.47M derived: sum of 2 quarters · filed 2026-02-27 | $168.05M derived: sum of 3 quarters · filed 2026-02-27 | $215.38M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2023-12-31 | $57.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $108.10M derived: sum of 2 quarters · filed 2026-02-27 | $155.43M derived: sum of 3 quarters · filed 2026-02-27 | $203.37M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $50.58M 10-Q · filed 2024-11-05 | $97.91M derived: sum of 2 quarters · filed 2024-11-05 | $145.84M 10-Q · filed 2024-11-05 | $190.09M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $47.33M 10-Q · filed 2024-08-06 | $95.26M 10-Q · filed 2024-08-06 | $139.51M derived: sum of 3 quarters · filed 2025-02-27 | $177.79M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $47.93M 10-Q · filed 2024-05-07 | $92.18M derived: sum of 2 quarters · filed 2025-02-27 | $130.46M derived: sum of 3 quarters · filed 2025-02-27 | $167.07M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $44.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $82.53M derived: sum of 2 quarters · filed 2025-02-27 | $119.14M derived: sum of 3 quarters · filed 2025-02-27 | $151.15M 10-K · filed 2025-02-27 | $149.16M 10-K · filed 2023-03-08 | |||
| 2022-09-30 | $38.28M 10-Q · filed 2023-11-09 | $37.75M 10-Q · filed 2022-11-09 | $74.89M derived: sum of 2 quarters · filed 2023-11-09 | $106.91M 10-Q · filed 2023-11-09 | $105.64M 10-Q · filed 2022-11-09 | $140.57M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-06-30 | $36.61M 10-Q · filed 2023-08-09 | $36.25M 10-Q · filed 2022-08-10 | $68.62M 10-Q · filed 2023-08-09 | $67.89M 10-Q · filed 2022-08-10 | $102.29M derived: sum of 3 quarters · filed 2024-02-27 | $125.12M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-03-31 | $32.01M 10-Q · filed 2023-05-09 | $31.64M 10-Q · filed 2022-05-06 | $65.68M derived: sum of 2 quarters · filed 2024-02-27 | $88.51M derived: sum of 3 quarters · filed 2024-02-27 | $109.27M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2021-12-31 | $33.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $56.50M derived: sum of 2 quarters · filed 2024-02-27 | $77.26M derived: sum of 3 quarters · filed 2024-02-27 | $94.04M 10-K · filed 2024-02-27 | $93.10M 10-K · filed 2022-03-04 | |||
| 2021-09-30 | $22.83M 10-Q · filed 2022-11-09 | $43.59M derived: sum of 2 quarters · filed 2022-11-09 | $60.37M 10-Q · filed 2022-11-09 | $75.76M derived: sum of 4 quarters · filed 2023-03-08 | ||||
| 2021-06-30 | $20.76M 10-Q · filed 2022-08-10 | $37.54M 10-Q · filed 2022-08-10 | $52.93M derived: sum of 3 quarters · filed 2023-03-08 | $64.35M derived: sum of 4 quarters · filed 2023-03-08 | ||||
| 2021-03-31 | $16.78M 10-Q · filed 2022-05-06 | $32.17M derived: sum of 2 quarters · filed 2023-03-08 | $43.59M derived: sum of 3 quarters · filed 2023-03-08 | $50.76M derived: sum of 4 quarters · filed 2023-03-08 | ||||
| 2020-12-31 | $15.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $26.80M derived: sum of 2 quarters · filed 2023-03-08 | $33.98M derived: sum of 3 quarters · filed 2023-03-08 | $44.04M 10-K · filed 2023-03-08 | ||||
| 2020-09-30 | $11.42M 10-Q · filed 2021-11-04 | $18.59M derived: sum of 2 quarters · filed 2021-11-04 | $28.65M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $7.17M 10-Q · filed 2021-08-05 | $17.24M 10-Q · filed 2021-08-05 | ||||||
| 2020-03-31 | $10.07M 10-Q · filed 2021-05-25 | |||||||
| 2019-12-31 | $35.32M 10-K · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |